Preferential response of cancer cells to zebularine - PubMed (original) (raw)
Preferential response of cancer cells to zebularine
Jonathan C Cheng et al. Cancer Cell. 2004 Aug.
Free article
Abstract
The frequent silencing of tumor suppressor genes by altered cytosine methylation and chromatin structural changes makes this process an attractive target for epigenetic therapy. Here we show that zebularine, a stable DNA cytosine methylation inhibitor, is preferentially incorporated into DNA and exhibits greater cell growth inhibition and gene expression in cancer cell lines compared to normal fibroblasts. In addition, zebularine preferentially depleted DNA methyltransferase 1 (DNMT1) and induced expression of cancer-related antigen genes in cancer cells relative to normal fibroblasts. Our results demonstrate that zebularine can be selective toward cancer cells and may hold clinical promise as an anticancer therapy.
Similar articles
- Zebularine: a candidate for epigenetic cancer therapy.
Bradbury J. Bradbury J. Drug Discov Today. 2004 Nov 1;9(21):906-7. doi: 10.1016/S1359-6446(04)03266-0. Drug Discov Today. 2004. PMID: 15501719 - Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells.
Cheng JC, Weisenberger DJ, Gonzales FA, Liang G, Xu GL, Hu YG, Marquez VE, Jones PA. Cheng JC, et al. Mol Cell Biol. 2004 Feb;24(3):1270-8. doi: 10.1128/MCB.24.3.1270-1278.2004. Mol Cell Biol. 2004. PMID: 14729971 Free PMC article. - Inhibition of DNA methylation and reactivation of silenced genes by zebularine.
Cheng JC, Matsen CB, Gonzales FA, Ye W, Greer S, Marquez VE, Jones PA, Selker EU. Cheng JC, et al. J Natl Cancer Inst. 2003 Mar 5;95(5):399-409. doi: 10.1093/jnci/95.5.399. J Natl Cancer Inst. 2003. PMID: 12618505 - Zebularine: a new drug for epigenetic therapy.
Yoo CB, Cheng JC, Jones PA. Yoo CB, et al. Biochem Soc Trans. 2004 Dec;32(Pt 6):910-2. doi: 10.1042/BST0320910. Biochem Soc Trans. 2004. PMID: 15506921 Review. - DNA methylation and cancer therapy.
Szyf M. Szyf M. Drug Resist Updat. 2003 Dec;6(6):341-53. doi: 10.1016/j.drup.2003.10.002. Drug Resist Updat. 2003. PMID: 14744498 Review.
Cited by
- Novel therapeutic agents in clinical trials: emerging approaches in cancer therapy.
Joshi DC, Sharma A, Prasad S, Singh K, Kumar M, Sherawat K, Tuli HS, Gupta M. Joshi DC, et al. Discov Oncol. 2024 Aug 11;15(1):342. doi: 10.1007/s12672-024-01195-7. Discov Oncol. 2024. PMID: 39127974 Free PMC article. Review. - Cytosine analogues as DNA methyltransferase substrates.
Wojciechowski M, Czapinska H, Krwawicz J, Rafalski D, Bochtler M. Wojciechowski M, et al. Nucleic Acids Res. 2024 Aug 27;52(15):9267-9281. doi: 10.1093/nar/gkae568. Nucleic Acids Res. 2024. PMID: 38966999 Free PMC article. - Methylation of the Vitamin D Receptor Gene in Human Disorders.
Gasperini B, Falvino A, Piccirilli E, Tarantino U, Botta A, Visconti VV. Gasperini B, et al. Int J Mol Sci. 2023 Dec 20;25(1):107. doi: 10.3390/ijms25010107. Int J Mol Sci. 2023. PMID: 38203278 Free PMC article. Review. - Nano-Regulator Inhibits Tumor Immune Escape via the "Two-Way Regulation" Epigenetic Therapy Strategy.
Liang S, Liu M, Mu W, Gao T, Gao S, Fu S, Yuan S, Liu J, Liu Y, Jiang D, Zhang N. Liang S, et al. Adv Sci (Weinh). 2024 Mar;11(9):e2305275. doi: 10.1002/advs.202305275. Epub 2023 Dec 18. Adv Sci (Weinh). 2024. PMID: 38110834 Free PMC article. - The Protective Effect of Zebularine, an Inhibitor of DNA Methyltransferase, on Renal Tubulointerstitial Inflammation and Fibrosis.
Koh ES, Kim S, Son M, Park JY, Pyo J, Kim WY, Kim M, Chung S, Park CW, Kim HS, Shin SJ. Koh ES, et al. Int J Mol Sci. 2022 Nov 14;23(22):14045. doi: 10.3390/ijms232214045. Int J Mol Sci. 2022. PMID: 36430531 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources